CETIRIZINE HYDROCHLORIDE
| Brand name | ZERVIATE |
|---|---|
| Active ingredient | CETIRIZINE HYDROCHLORIDE |
| Strength | EQ 0.24% BASE |
| Dosage form | SOLUTION/DROPS |
| Route | OPHTHALMIC |
| Modality | Small molecule |
| FDA approval | May 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9254286*PED | January 2033 | — |
| 9254286 | July 2032 | product |
| 8829005*PED | September 2030 | — |
| 9993471 | March 2030 | use U-1680 |
| 8829005 | March 2030 | use U-1680 |
| 9750684 | March 2030 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.